Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

FNCH Finch Therapeutics

Watchlist
2.835
+0.155+5.78%
Trading Session 06/30 14:55 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.870
Open
2.597
Turnover
161.03K
Low
2.540
Pre Close
2.680
Volume
59.65K
Market Cap
134.83M
P/E(TTM)
Loss
52wk High
17.390
Shares
47.56M
P/E(Static)
Loss
52wk Low
1.712
Float Cap
63.55M
Bid/Ask %
-81.82%
Historical High
22.500
Shs Float
22.42M
Volume Ratio
0.27
Historical Low
1.712
Dividend TTM
--
Div Yield TTM
--
P/B
0.75
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.27%
Amplitude
12.31%
Avg Price
2.699
Lot Size
1
Float Cap
63.55M
Bid/Ask %
-81.82%
Historical High
22.500
Shs Float
22.42M
Volume Ratio
0.27
Historical Low
1.712
Dividend TTM
--
P/B
0.75
Dividend LFY
--
Turnover Ratio
0.27%
Amplitude
12.31%
Avg Price
2.699
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company’s lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn’s disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
CEO: Smith Ph.D., Mark Burnham
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top